Financial Daily from THE HINDU group of publications
Tuesday, Oct 04, 2005

Port Info

Group Sites

Corporate - Outlook

Ranbaxy sees big scope in anti-retrovirals

Nithya Subramanian

New Delhi , Oct. 3

FOLLOWING the recent approvals by the US Food and Drug Administration for some of its anti-retroviral drugs (ARVs) and the re-listing by the World Health Organisation, Ranbaxy Laboratories Ltd is expecting some large orders, especially under George Bush's $15-billion President's Emergency Plan for AIDS Relief (PEPFAR).

In fact, Mr Malvinder Mohan Singh, President (Pharmaceuticals), Ranbaxy, had earlier told Business Line, "We hope considerable business comes our way under the PEPFAR project." Under the five-year global initiative to combat the HIV/AIDS epidemic in the African and Caribbean region, about half of the money would be used for treatment of infected persons.

Ranbaxy will launch ARVs in the US market as and when patents for specific drugs expire. For instance, it has launched Zidovudine tablets in the US and recently got approval for Nevirapine, which is used to reduce mother to child disease transmission.

In 2004, Ranbaxy exported ARVs to over 50 countries across Asia, Africa, CIS and Latin America.

NGO market: The company said several non-governmental organisations (NGOs) have started buying from it.

In some of the African countries, the Clinton Foundation along with Ranbaxy and some other generic drug manufacturers have agreed to work together to supply AIDS drugs.

"In those countries, we supply ARVs at highly discounted prices," said a company official.

Anti-AIDS drugs have not yet started contributing significantly to the company's turnover.

"Given the large revenue base of the company, ARVs make only a marginal contribution to the company's topline and bottomline. We expect robust growth in ARV revenues as treatment is being ramped up in most developing countries," said the official.

Pricing pressure: There is a lot of pricing pressure on ARVs and the company does not expect the situation to change, as NGOs, humanitarian agencies and Ministries of Health are the big purchasers. "Prices have already bottomed out and unless something radical happens, we don't see prices falling much further. However, the recent hike in the value of the rupee could lead to an increase in prices," he added.

Competition: Meanwhile, analysts tracking the sector felt that the ARV business is a high volume, low margin one. "The increase in the incidence of HIV/AIDS infections will, nevertheless, ensure that the company has a steady order book. But competition is also intense with other Indian companies such as Cipla, Matrix and Aurobindo Pharma in the same space.

"They too are getting regulatory approvals and, therefore, the segment is commoditised," said a Mumbai-based analyst.

However, they further said the supply of anti-AIDS drugs to high-profile programmes could help the company build an image.

"As volumes under these welfare plans go up, the company may be able have a better bargaining power with their distributors in the international market," the analyst said.

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Share Infoline Tata Safari Dicor

Stories in this Section
NTC to lease out 30 mills to pvt sector — Short of cash for modernising all mills

GHCL hikes soda ash price by Rs 400 per tonne
Maruti hikes prices, spares Swift
TN Industrial Explosives to launch new product range
Glenmark's Goa plant gets USFDA nod
Ircon to pay Rs 20 cr dividend
Global merger not to change Boots Piramal operations
Management lessons from the Mahatma
KTM Jewellery plans expansion
GAIL signs deal for equity participation in Myanmar blocks
Manpower India, ABC Consultants set up joint venture
Toonz, Vijay Amritraj firm tie up for animation venture
Ministry not to intervene in GAIL-ONGC gas deal
Phillips Carbon Black studying options to raise funds for power plant
Ranbaxy sees big scope in anti-retrovirals
GAIL in talks to buy LNG from Australia
Same Deutz-Fahr plans Indian export hub
ACC bullish on TN, Kerala markets
Tata Motors Sept sales up
Skoda sales rise 31 pc
ONGC appoints 2 new directors
New CEO for Siticable

The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | The Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright 2005, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line